Silo pharma announces successful dosing of patients suffering from parkinson's disease in psilocybin study

Study is examining effects of psilocybin on inflammatory markers englewood cliffs, n.j., may 19, 2022 (globe newswire) --  silo pharma, inc . (otcqb: silo), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it in conjunction with the university of california san francisco (ucsf), researchers have successfully dosed patients suffering from parkinson's disease. as part of this study, the researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of parkinson's.
SILO Ratings Summary
SILO Quant Ranking